Investigation Report on China Letrozole Market, 2010-2019
Description
Currently, breast cancer has become the first killer of women with new cases reaching about 1.2 million and 0.5 million women dying of it each year.
According to Breast Cancer in China which was published in 2014, the number of new cases and deaths in China respectively accounted for 12.2% and 9.6% of the world sum. And the growth rate of China doubled that of the world. According to the statistics, breast cancer with increasing incidence is the most common malignant cancer for Chinese women. And the average age at onset is 10-15 years younger than that in Europe and America. As the third generation of aromatase inhibitor developed by Novartis, letrozole entered United Kingdom first in 1996 and the US in 1997 before being widely used as the first-line drug for advanced breast cancer and as the second-line drug for breast cancer. At home, Jiangsu Hengrui Medicine Co., Ltd was approved to market letrozole under the trade name of Furui in 1999, followed by Femara of Novaris in 2003.
According to CRI’s market survey, letrozole develops fast after entering China with sales value rising from about CNY 20 million in 2005 to over CNY 300 million in 2014 and CAGR during this period reaching 35.1%. As Femara of Novartis is priced two times higher than local products, its sales volume only accounted for less than 50% of the sum despite its market share of 73.62% in 2014. The gradual decrease in Novatis’s market share, however, constitutes a great opportunity for local enterprises. Currently, there are only two kinds of letrozole available in the Chinese market, indicating a high entry barrier and a large market.
Studies have shown the uniqueness of breast cancer in China: special fertility pattern due to family planning as well as modern lifestyle like high-fat diet and little exercise increases the risk of breast cancer.
It is expected that letrozole will enjoy a vast demand in China.
Readers can get at least the following information through this report:
Currently, breast cancer has become the first killer of women with new cases reaching about 1.2 million and 0.5 million women dying of it each year.
According to Breast Cancer in China which was published in 2014, the number of new cases and deaths in China respectively accounted for 12.2% and 9.6% of the world sum. And the growth rate of China doubled that of the world. According to the statistics, breast cancer with increasing incidence is the most common malignant cancer for Chinese women. And the average age at onset is 10-15 years younger than that in Europe and America. As the third generation of aromatase inhibitor developed by Novartis, letrozole entered United Kingdom first in 1996 and the US in 1997 before being widely used as the first-line drug for advanced breast cancer and as the second-line drug for breast cancer. At home, Jiangsu Hengrui Medicine Co., Ltd was approved to market letrozole under the trade name of Furui in 1999, followed by Femara of Novaris in 2003.
According to CRI’s market survey, letrozole develops fast after entering China with sales value rising from about CNY 20 million in 2005 to over CNY 300 million in 2014 and CAGR during this period reaching 35.1%. As Femara of Novartis is priced two times higher than local products, its sales volume only accounted for less than 50% of the sum despite its market share of 73.62% in 2014. The gradual decrease in Novatis’s market share, however, constitutes a great opportunity for local enterprises. Currently, there are only two kinds of letrozole available in the Chinese market, indicating a high entry barrier and a large market.
Studies have shown the uniqueness of breast cancer in China: special fertility pattern due to family planning as well as modern lifestyle like high-fat diet and little exercise increases the risk of breast cancer.
It is expected that letrozole will enjoy a vast demand in China.
Readers can get at least the following information through this report:
- market size of letrozole in China
- competitive landscape of letrozole market in China
- price of letrozole made by different enterprises in China
- market outlook of letrozole in China
- manufacturers of antitumor agents
- investors/research institutions interested in Chinese medicine market
1 RELATED CONCEPTS OF LETROZOLE
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF LETROZOLE IN CHINA
2.1 Patent and Approval Information of Letrozole in China
2.2 Major Manufacturers
2.3 Market Size
3 SSURVEY ON LETROZOLE SALES IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR LETROZOLE MANUFACTURERS IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF LETROZOLE IN CHINA, 2010-2014
6 REFERENCE PRICE OF LETROZOLE IN CHINESE HOSPITALS IN 2014
6.1 Jiangsu Hengrui Medicine Co., Ltd (Trade Name: Furui)
6.2 Novartis AG (Switzerland) (Trade Name: Femara)
7 MAJOR MANUFACTURERS OF LETROZOLE IN CHINESE MARKET, 2010-2014
7.1 Jiangsu Hengrui Medicine Co., Ltd
7.2 Novartis AG (Switzerland)
8 MARKET OUTLOOK OF LETROZOLE IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
TABLE OF SELECTED CHARTS
Chart Patent of Letrozole in China
Chart Approval Information of Letrozole in China
Chart Letrozole Sales in China
Chart Sales Value of Letrozole in China, 2010-2014
Chart Sales Value of Letrozole in Some Regions in China, 2010-2014
Chart Sales Volume of Letrozole in China, 2010-2014
Chart Sales Volume of Letrozole in Some Regions in China, 2010-2014
Chart Market Share of TOP2 Letrozole Manufacturers for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Letrozole Made by Novartis (Switzerland) in China, 2010-2014
Chart Sales Value and Market Share of Letrozole Made by Jiangsu Hengrui in China, 2010-2014
Chart Price of Letrozole Made by Jiangsu Hengrui Medicine Co., Ltd in Some Chinese Cities in 2014
Chart Price of Letrozole Made by Novartis AG (Switzerland) in Some Chinese Cities in 2014
COMPANIES MENTIONED
Jiangsu Hengrui Medicine Co., Ltd; Novartis AG
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF LETROZOLE IN CHINA
2.1 Patent and Approval Information of Letrozole in China
2.2 Major Manufacturers
2.3 Market Size
3 SSURVEY ON LETROZOLE SALES IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR LETROZOLE MANUFACTURERS IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF LETROZOLE IN CHINA, 2010-2014
6 REFERENCE PRICE OF LETROZOLE IN CHINESE HOSPITALS IN 2014
6.1 Jiangsu Hengrui Medicine Co., Ltd (Trade Name: Furui)
6.2 Novartis AG (Switzerland) (Trade Name: Femara)
7 MAJOR MANUFACTURERS OF LETROZOLE IN CHINESE MARKET, 2010-2014
7.1 Jiangsu Hengrui Medicine Co., Ltd
7.2 Novartis AG (Switzerland)
8 MARKET OUTLOOK OF LETROZOLE IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
TABLE OF SELECTED CHARTS
Chart Patent of Letrozole in China
Chart Approval Information of Letrozole in China
Chart Letrozole Sales in China
Chart Sales Value of Letrozole in China, 2010-2014
Chart Sales Value of Letrozole in Some Regions in China, 2010-2014
Chart Sales Volume of Letrozole in China, 2010-2014
Chart Sales Volume of Letrozole in Some Regions in China, 2010-2014
Chart Market Share of TOP2 Letrozole Manufacturers for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Letrozole Made by Novartis (Switzerland) in China, 2010-2014
Chart Sales Value and Market Share of Letrozole Made by Jiangsu Hengrui in China, 2010-2014
Chart Price of Letrozole Made by Jiangsu Hengrui Medicine Co., Ltd in Some Chinese Cities in 2014
Chart Price of Letrozole Made by Novartis AG (Switzerland) in Some Chinese Cities in 2014
COMPANIES MENTIONED
Jiangsu Hengrui Medicine Co., Ltd; Novartis AG
